We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FHI:NYSEFederated Hermes, Inc. Analysis

Data as of 2026-05-19 - not real-time

$54.69

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Federated Hermes posted a 13.1% year‑over‑year revenue increase to $479 million and a GAAP EPS of $5.15, comfortably beating consensus estimates, while maintaining a robust gross margin of 68% and an ROE of 33.8%. Its valuation appears attractive – a trailing P/E of 10.6 versus an industry average of 16.6 and a dividend yield of 2.57% backed by a modest 26% payout ratio, indicating sustainable cash flow. However, the stock is trading below its 20‑day (55.67) and 50‑day (56.32) SMAs, with a bearish MACD crossover and decreasing volume, suggesting short‑term pressure near the $52.35 support level.
The company’s balance sheet is solid, with cash exceeding debt and free cash flow of $364 million, while the strategic push on assets under management and recent executive appointment support a medium‑term upside toward the $58.39 resistance. Given the neutral market trend, moderate beta (≈0.8) and 30‑day volatility of 33%, the risk profile is balanced, making a hold for the near term and a buy for medium to long horizons appropriate.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and price below short‑term moving averages
  • Proximity to technical support at $52.35
  • Attractive dividend yield providing downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 13% revenue growth and record AUM
  • Undervalued relative to industry peers (P/E 10.6 vs 16.6)
  • Potential upside to resistance around $58.40

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong ROE (33.8%) and consistent free cash flow
  • Sustainable dividend with low payout ratio
  • Strategic leadership additions and continued asset management positioning

Key Metrics & Analysis

Financial Health

Revenue Growth13.10%
Profit Margin21.47%
P/E Ratio10.6
ROE33.76%
ROA15.33%
Debt/Equity35.67
P/B Ratio3.3
Op. Cash Flow$311.9M
Free Cash Flow$364.8M
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI44.9
Support$52.35
Resistance$58.39
MA 20$55.67
MA 50$56.32
MA 200$53.31
MACDBearish
VolumeDecreasing
Fear & Greed Index89.38

Valuation

Fair Value$110.34
Target Price$55.43
Upside/Downside1.35%
GradeUndervalued
TypeBlend
Dividend Yield2.57%

Risk Assessment

Beta0.80
Volatility33.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.